Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of semaglutide injection versus Novo Nordisk's Ozempic in adults with type 2 diabetes inadequately controlled on metformin
CTR20240787Phase 3Completed
- Sponsor
- Chengdu Better Pharmaceutical
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Chengdu Better Pharmaceutical. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240787.